CN108066723A - A kind of natural drug composition of prevention and cure of cardiovascular disease and its application - Google Patents
A kind of natural drug composition of prevention and cure of cardiovascular disease and its application Download PDFInfo
- Publication number
- CN108066723A CN108066723A CN201611007653.8A CN201611007653A CN108066723A CN 108066723 A CN108066723 A CN 108066723A CN 201611007653 A CN201611007653 A CN 201611007653A CN 108066723 A CN108066723 A CN 108066723A
- Authority
- CN
- China
- Prior art keywords
- ginger
- fish oil
- gingerol
- composition according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
The present invention relates to a kind of pharmaceutical compositions for the anti-cardiovascular disease being combined by fish oil and Ginger P.E.Experimental researches prove that said composition improves significantly for disease of cardiovascular system tool and therapeutic effect.Raw material sources used in the present invention extensively, Nantural non-toxic, Small side effects, cost it is relatively low, there is wide actual application value.
Description
Technical field
The invention belongs to medicine, field of health care products, are related to a kind of natural drug composition for treating angiocardiopathy, specifically
The pharmaceutical composition and its application in terms of angiocardiopathy is treated that ground is related to fish oil and Ginger P.E composition.
Background technology
Angiocardiopathy is one of disease that the world today threatens human health most serious, and morbidity and mortality are super
Cross tumor disease and the position that leaps to the first.In recent years, with the extension of population average life span and the raising of people's living standard, the heart
Vascular disease gradually increases, and the trend of increasingly rejuvenation is presented in age of onset.Epidemiological analysis shows that the whole world is every
Year about 15,000,000 people die of angiocardiopathy, and China also has nearly 4,000,000 people to die of this disease every year, account for the 3/5 of death toll with
On, angiocardiopathy is just gradually substituting other illnesss as Chinese population or even the primary disease of population in the world death.According to
2014 newest《Chinese cardiovascular disease report》It has been shown that, by the end of the year 2014, China's cardiovascular patient rises to 2.9 hundred million
People, wherein 2.7 hundred million people of hyperpietic, about 7,000,000 people of patients with cerebral apoplexy, 2,500,000 people of myocardial infarction patient, heart failure patient
4500000 people, 5,000,000 people of patients with cor pulmonale, 2,500,000 people of Patients With Rheumatic Valvular Disease, 2,000,000 people of patients with congenital heart.Such as
Fruit includes the circulation system disease of the indirect correlations such as hyperlipidemia, diabetes, coronary heart disease, thrombus, atherosclerosis, number of patients
And annual death toll will be more huge.The generation of disease of cardiovascular system is mainly different with dysarteriotony, pathoglycemia, blood fat
Often, many factors such as metabolic syndrome, obesity, unreasonable meals, amount of exercise reduction, smoking are related.
The pathogenesis of angiocardiopathy is sufficiently complex, and dynamic process is presented.For a long time, anti-cardiovascular disease
The research and development of sick new drug achieve tremendous development, but clinically common drug is still based on the Western medicine of single target spot effect, this is aobvious
The angiocardiopathy of control multipath pathogenesis is so not enough to, and Western medicine is often with substantial amounts of side effect.With research
It deepens continuously, the medication requirement based on complicated interpretation of the cause, onset and process of an illness disease, the advantage of compound medicine is just more prominent, particularly with natural compounds
The compound medicine of object ingredient exploitation is increasingly paid attention to be subject to market.With the cumulative year after year of cardiovascular disease incidence rate, this gives
Social medicine spending brings great pressure, but is said from another side, this exploitation also for new anti-cardiovascular drugs provides
The wide market space.China's animal and plant resource enriches, and strong money is provided to develop pure natural Compound Resisting cardiovascular drugs
Source ensures.
It is well known that containing a large amount of unrighted acids in fish oil, using EPA and DHA as the polyunsaturated fatty acid of representative
With extensive pharmacological action, it is beneficial to health.EPA and DHA is the nutriment that mammal itself cannot synthesize,
It is highly unsaturated fatty acid needed by human, plays the role of in growth in humans, growth course particularly important.EPA/DHA
It is positive infant intelligent development, promotion nervous system development, anti-inflammatory, protection cardiovascular system, anticancer etc. is promoted to have
Effect.The approach that EPA/DHA reduces angiocardiopathy incidence is diversified, mainly by improving lipid-metabolism reduction
The incidence of angiocardiopathy.If EPA/DHA can reduce the level of serum triglyceride, cholesterol, low-density lipoprotein, increase
Increase density lipoprotein levels to reduce the deposition of lipid in blood vessel, enhance blood vessel inner skin cell function, prevention of arterial is athero- hard
Change.EPA/DHA can inhibit the synthesis of endogenous cholesterol simultaneously, increase the excretion of cholesterol, change aliphatic acid group in lipoprotein
Into increase blood fluidity, so as to prevention of cardiovascular disease.
Ginger for herbaceos perennial ginger (Zingiber Of ficinale Roscoe) rhizome also known as ground it is pungent, hundred
Peppery cloud is a kind of tubers pungent and fragrant flavorings and international trade so far widely planted in world wide shaped like palmate
In a kind of mostly important tubers fragrance.Simultaneously in China or even entire Asia, it or a kind of traditional medicine eat two
With plant, there is expelling cold and relieving exterior syndrome, warming middle energizer to stop vomiting, Back to Yang Tongmai, eliminating dampness dissolving phlegm.Modern medicine study shows that ginger has
Anti-freezing, anti-oxidant, antitumor, boosting cardiac stimulant, reducing blood lipid, antiatherosclerosis, protection stomach lining, hepatic cholagogic, anti-inflammatory, town
The multiple efficacies such as cough, Anti-dizzy anti-emetic, Central nervous inhibition.Gingerol (gingerol) is the main spicy substance in ginger, ginger
Phenol includes single aromatic ring and double two classes of aromatic ring heptane, and wherein single aromatic ring class gingerol includes 6-gingerol, 8-gingerol, 10-gingerol, 12- again
The ingredients such as gingerol are the primary bioactivity substances in ginger.Gingerol class chemical composition all has similar chemical constitution in ginger,
There is beta-hydroxy ketone structure.With 6-gingerol content highest in gingerol, bioactivity is also most strong, therefore 6-gingerol is frequently as commenting
The objective indicator of valency ginger and its drug quality.
Have no that fish oil is united and applied in the report in terms of the prevention and/or treatment of angiocardiopathy with Ginger P.E at present
Road.
The content of the invention
It is an object of the present invention to provide a kind of curative for effect, safe ready, the anti-cardiovascular disease medicines of Small side effects
Compositions, specifically said composition is that fish oil is formed with Ginger P.E.
A preferred embodiment of pharmaceutical composition according to the present invention, the fish oil is from mackerel, tuna, three texts
The abyssal fishes such as fish, sturgeon, long tail anchovy, sardine, catfish, trout, wherein at least comprising docosahexaenoic acid（DHA）, two
Ten carbon 5 alkene acids（EPA）, arachidonic acid（AA）, gamma-Linolenic acid（GLA）The one or more in polyunsaturated fatty acids are waited,
Total content of polyunsaturated fatty acid >=8% in wherein described fish oil.
A preferred embodiment of pharmaceutical composition according to the present invention, the Ginger P.E include at least 6-gingerol,
One or more in the ginger phenolic compounds such as 8-gingerol, 10-gingerol, 12- gingerols, wherein gingerol class in the Ginger P.E
Compounds content >=25%；
Further, the ginger phenolic compounds are preferably 6-gingerol.
Ginger phenolic compounds of the present invention have the chemical structural formula of formula I-IV：
Wherein：
I n=4,6-gingerol；II n=6,8-gingerol；III n=8,10-gingerol；IV n=10,12- gingerol.
A preferred embodiment of pharmaceutical composition according to the present invention, composition are the raw material structures by following weight proportion
Into：
1-250 parts of fish oil, 1-250 parts of Ginger P.E；
Further, said composition is made of the raw material of following weight proportion：
20-200 parts of fish oil, 15-180 parts of Ginger P.E；
Further, said composition is made of the raw material of following weight proportion：
50-120 parts of fish oil, 30-150 parts of Ginger P.E.
A preferred embodiment of pharmaceutical composition according to the present invention, wherein can also contain one or more with phase
Same or shares activity other active components.
A preferred embodiment of pharmaceutical composition according to the present invention, wherein the other active components are selected from naturally
Plant extracts and/or chemical synthetic drug.
A preferred embodiment of pharmaceutical composition according to the present invention, wherein one or more can also be contained pharmaceutically
Acceptable carrier or excipient.
It is a further object to provide pharmaceutical composition as defined above in production for preventing and treating painstaking effort
Application in pipe disease medicament.The angiocardiopathy includes but not limited to atherosclerosis, coronary heart diseases and angina pectoris, brain blood
The diseases such as bolt, hypertension, hyperglycaemia, hyperlipidemia, myocardial infarction, ischemic pulmonary heart disease.
The present composition combines fish oil and is damaged in regulating plasma lipid and Ginger P.E in resisting myocardial ischemia property, is anti-oxidant
Etc. the advantages of, the drug prepared shows through pharmacological research with reducing blood lipid, antiatherosclerosis, resisting myocardial ischemia property
The extensive anti-cardiovascular disease effect such as damage, anti-oxidant.Therefore the present composition can be as a kind of new anti-angiocarpy
Medicine is widely used in the prevention and treatment of clinical cardiovascular disease.
Present invention combination can pharmaceutically connect containing fish oil as active component and Ginger P.E and one or more
The carrier and/or diluent received.If necessary, the present composition can also contain one or more with same or similar effect
Natural or chemical synthesis other active components.Natural other active components include but not limited to leaf of negundo chastetree, Vitex negundo var cannabifolia
It is son, pigeonpea, sensitive plant, eleusine indica, Chinese violet, passionflower, leaves of Hawthorn, uncaria, gynostemma pentaphylla, ginkgo leaf, radix scutellariae, lotus leaf, red
It red-spotted stonecrop, Radix Glycyrrhizae, trollflower, Ficus microcarpa, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, subprostrate sophora, cattail pollen, safflower, kuh-seng etc. or their active component and carries
Take object.The other active components of chemical synthesis are with including but not limited to nitroglycerin, Isosorbide Nitrate, nifedipine, hydrochloric acid
Your sulphur Zhuo, Propranolol, Propafenone, captopril, Irb, rice sieve that, Lovastatin, Bezafibrate, clofibrate,
Ji Feibei top grades.The present composition is improved by the multipaths such as Adjust-blood lipid, blood pressure lowering, the damage of resisting myocardial ischemia property, anti-oxidant
Cardiovascular disease systemic symptom has for disease of cardiovascular systems such as coronary heart disease, cerebral thrombus, myocardial infarction, atherosclerosis
Preferable preventive and therapeutic action.
The present composition can be prepared according to known method in pharmaceuticals industry piece agent, capsule, pill, pulvis,
Suppository, solution, suspension etc..Wherein it is preferred that suitable for capsule and tablet through gastrointestinal administration.It is corresponding preparing
During the preparation of oral administration, sucrose, lactose, galactolipin, cornstarch, gelatin, microcrystalline cellulose, micro mist silicon can be used
Glue, carboxymethyl cellulose etc. are used as carrier or excipient.
In addition it is also possible to the present composition is prepared into using any means known in pharmaceuticals industry and complementary ingredient suitable
In the solution or suspension of parenteral route, distilled water, water for injection, isotonic sodium chlorrde solution or Portugal can be used
Grape sugar juice either low concentration phosphate buffer solution as carrier or diluent.It can be in these parenteral administrations
Other one or more auxiliary elements or additive are added in preparation, such as ascorbic acid can be used to be used as antioxidant
Sodium benzoate etc. is used as preservative.In these formulations, can also containing other appropriate solubilizer, disintegrant, lubricant,
Toner, dispersant or surfactant.
Following embodiment is intended to further illustrate the present composition rather than the limitation present invention.Without prejudice to the present invention
On the premise of spirit and principle, any modifications or changes carried out to inventing indivedual technical steps fall within present invention protection model
In enclosing.
Specific embodiment
Embodiment 1
100g fish oil 200g microcrystalline celluloses are absorbed into mixing, add 150g Ginger P.Es, 200g corns is then added in and forms sediment
Powder, 100g microcrystalline celluloses, 100g sodium carboxymethyl starches, 50g PVP K30s are pelletized, dry, whole grain, are packed into after mixing
No. 1 capsule is made 2000 up to capsule.
Embodiment 2
150g fish oil 200g microcrystalline celluloses are absorbed into mixing, add 100g Ginger P.Es, 200g corns is then added in and forms sediment
Powder, 100g microcrystalline celluloses, 100g sodium carboxymethyl starches, 50g PVP K30s are pelletized, dry, whole grain, are packed into after mixing
No. 1 capsule is made 2000 up to capsule.
Embodiment 3
60g fish oil 180g microcrystalline celluloses are absorbed into mixing, add 130g Ginger P.Es, 260g corns is then added in and forms sediment
Powder, 125g microcrystalline celluloses, 125g sodium carboxymethyl starches, 60g PVP K30s are pelletized, dry, whole grain, are added in after mixing
Moderate lubrication agent is pressed into tablet, piece weight 0.5g or so.
Embodiment 4
80g fish oil 180g microcrystalline celluloses are absorbed into mixing, add 110g Ginger P.Es, 260g corns is then added in and forms sediment
Powder, 125g microcrystalline celluloses, 125g sodium carboxymethyl starches, 60g PVP K30s are pelletized, dry, whole grain, are added in after mixing
Moderate lubrication agent is pressed into tablet, piece weight 0.5g or so.
Embodiment 5
70g Macrogol 4000s are weighed, are melted in water-bath, 60g fish oil, 45g Ginger P.Es is then added in, stirs evenly,
It is poured into incubator, regulating thermostatic device makes liquid be instilled at 80-90 DEG C in cooled atoleine, after dripping off, by medicine
Ball, which is poured on filter paper, blots paraffin oil, and pill is made.
Embodiment 6
Fish oil 20g, Ginger P.E 30g are weighed respectively, add in glycerol triacetate 25g, Macrogol 600 70g, Tween-80
Soft capsule is pressed on encapsulating machine after the auxiliary materials such as 15g, vitamin C 10g dissolving mixing.
Embodiment 7
120g fish oil 220g microcrystalline celluloses are absorbed into mixing, add 120g Ginger P.Es, 260g corns is then added in and forms sediment
Powder, 125g microcrystalline celluloses, 125g sodium carboxymethyl starches, 60g PVP K30s are pelletized, dry, whole grain, then after mixing
Pack is made granule, every bag of 2.5g or so.
Embodiment 8
25g fish oil, 75g Ginger P.Es are taken, adds the common medicinal supplementary material such as preparations such as vitamin C, sodium carboxymethyl starch, EDTA
Into clinically-acceptable oral liquid.
Pharmacodynamic experiment
1 present composition of test example is to pituitrin（Pit）Cause the influence of acute myocardial ischemia electrocardiogram
Health, normal ECG rat 60 are taken, is randomly divided into 6 groups, every group 10, half male and half female.The daily gastric infusion 1 of each group
Secondary, successive administration 7 days, Normal group gives normal saline.Dosage is shown in Table 1, and positive drug control group is Radix Salviae Miltiorrhizae
Dripping pill.The present composition is prepared by embodiment 1,2, and dosage is calculated by the actually active component content of composition.Last is given
After medicine 1 it is small when, each group in sublingual vein inject Pit, dosage be 1U/kg weight.The electrocardiogram of record 20min after having injected,
ST sections and T ripple situations of change in injection of pituitrin 30 seconds are measured, the results are shown in Table 1.
1 inventive composition of table is to pituitrin（Pit）Cause the influence of acute myocardial ischemia electrocardiogram
| Group | Dosage | ST sections of variations（MV） | T ripples change（MV） |
| Control group | - | 0.16±0.05 | 0.24±0.04 |
| 6-gingerol group | 100mg/kg | 0.12±0.02** | 0.17±0.04** |
| EPA groups | 100mg/kg | 0.13±0.04* | 0.24±0.06* |
| Embodiment 1 | 150mg/kg | 0.10±0.03*** | 0.16±0.01*** |
| Embodiment 2 | 150mg/kg | 0.10±0.02*** | 0.14±0.04*** |
| Danshen Root dropping ball group | 250mg/kg | 0.11±0.06** | 0.17±0.03** |
Note：Compared with the control group*P ＜ 0.05,**P ＜ 0.01,***P ＜ 0.001.
Such as table 1, control group after pituitrin is given, substantially raise by ECG ST section and T ripples, show modeling into
Work(.Compared with the control group, the variation for the Acute Myocardial Ischemia in Rats electrocardiogram that each experimental group is induced for pituitrin has
All apparent improvement result.But in general, the present composition is compared with being used alone having in fish oil and Ginger P.E
Effect element monomers EPA and 6-gingerol effect become apparent.
The influence for the mouse cardiac muscle ischemia model that 2 present composition of test example induces isoprel
Mouse 70 is taken, is divided into 7 groups by weight, started daily gastric infusion once on 7th, dosage is shown in Table（By active ingredient
Content calculation）, Normal group and model group gavage normal saline.It is administered the 6-8 days, life is subcutaneously injected in Normal group
Brine 10ml/kg is managed, isoprel 4mg/kg is subcutaneously injected in remaining group, and 24 is small after last gives isoprel
When, after socket of the eye venous blood sampling, measure lactic dehydrogenase in mice serum（LDL）And creatine phosphokinase（CPK）Content, flesh group of coring
Knit measure malonaldehyde（MDA）Content.It the results are shown in Table 2.
The influence for the mouse cardiac muscle ischemia model that 2 present composition of table induces isoprel
| Group | Dosage | LDL（U/dL） | CPK（U/dL） | MDA（nmol/L） |
| Normal group | - | 751.8±84.6** | 6.72±0.75** | 53.3±12.65* |
| Model group | - | 911.1±89.8 | 12.22±3.89 | 76.7±8.32 |
| 6-gingerol group | 100mg/kg | 748.4±86.9** | 8.31±0.67* | 50.2±12.2* |
| EPA groups | 100mg/kg | 799.6±64.8* | 9.89±0.92 | 54.2±8.97* |
| Embodiment 1 | 150mg/kg | 701.2±51.7*** | 7.66±0.84** | 51.6±10.21* |
| Embodiment 2 | 150mg/kg | 685.3±75.4*** | 7.34±1.06** | 54.5±6.92* |
| Danshen Root dropping ball group | 250mg/kg | 745.8±84.6** | 8.82±1.27* | 52.8±8.91* |
Note：Compared with the control group*P ＜ 0.05,**P ＜ 0.01,***P ＜ 0.001
The result shows that 6-gingerol, EPA and the present composition can significantly reduce the myocardial ischemia caused by isoprel
In mice serum in the activity of LDH, CPK and cardiac muscular tissue malonaldehyde content.But Integrated comparative, the present composition should
With with obvious effects better than other test groups, show between composition of the present invention that there is apparent synergistic function.
The influence for the rats of hyperlipoidemic modle that 3 present composition of test example induces high lipid food
Rat adapts to raising after a week after buying back, by serum total cholesterol（TC）Level is grouped：Normal group, hyperlipidemia
Model group, positive drug control group（Gemfibrozil Capsules）, EPA, 6-gingerol, present composition group（It is prepared by embodiment 1,2）.Just
Normal control group and model group give isometric distilled water, and continuous gavage is after 5 days, and in addition to Normal group, remaining each group animal is equal
The Fat Emulsion of feeding 10ml/kg daily（Include 8%, lard 16%, No. 3 cholate 3%, methylthiouracil 0.25%, propylene glycol 18%
With Tween-80 16%）And by 3 dosage gastric infusion of table, continuous feeding after two weeks, when each group Rat Fast 16 is small after take a blood sample and measure
Serum total cholesterol（TC）And triglycerides（TG）.
The influence for the rats of hyperlipoidemic modle that 3 present composition of table induces high lipid food
Note：Compared with model group*P ＜ 0.05,**P ＜ 0.01.
From table 3 it can be seen that apparent downward trend is presented in the blood lipid level of each experimental group, wherein consolidating for the total courage of serum
The adjusting of alcohol is more notable.The present composition is substantially better than in the effect for adjusting blood fat is used alone EPA, 6-gingerol, says
There is significant synergistic function between bright each ingredient of the present composition.
Influence of 4 present composition of test example to isoprel Myocardial Ischemia resist oxygen lack
Male mice 70 is taken, is divided into 7 groups by weight, dosage gastric infusion 1 week as shown in table 4 is administered daily 1 time, in last
30 minutes after administration, in addition to blank control group, isoprel 5ml/kg is subcutaneously injected in remaining test group, is done after 15 minutes resistance to
Anoxic is tested.Record mouse hypoxia endurance time such as table 4.
Influence of 4 present composition of table to isoprel Myocardial Ischemia resist oxygen lack
Note：Compared with the control group*P ＜ 0.05,**P ＜ 0.01,***P ＜ 0.001.
It is lacked the experimental results showed that EPA, 6-gingerol and the present composition can significantly improve the resistance to of myocardial ischemia mouse
Oxygen ability, can notable life span of the lengthening model mouse in anaerobic environment.Comprehensive Experiment data can be seen that of the present invention group
It closes object to have a clear superiority compared with EPA, the 6-gingerol being used alone, prompts the present invention that combination has synergistic effect.
Influence of 5 present composition of test example to blood stasis model hemorheology of rat index
Rat 70 is taken, is randomly divided into 7 groups, every group 10, half male and half female is administered one week, last according to 5 dosage continuous gavage of table
The previous day is administered, each group rat skin lower injection adrenalin hydrochloride 0.8mg/kg is twice, small per minor tick 8 in addition to Normal group
When.Rat was as a child placed in 0-2 DEG C of ice water moderate stimulation 10 minutes by injection 4 for the first time.Be deprived of food but not water 12 it is small when after, last dose
Once, taken a blood sample when 1 is small after administration with chloral hydrate anesthesia, abdominal aorta, heparin sodium anti-freezing, blood viscometer measures whole blood than viscous
Degree（High shear rate 120/s, low shear rate 30/s）, plasma viscosity, the results are shown in Table 5.
Influence of 5 present composition of table to blood stasis model hemorheology of rat index
Note：* P ＜ 0.05 compared with the control group, * * P ＜ 0.01
Compared with normal group, model group rats whole blood contrast viscosity, plasma viscosity all significantly improve, and illustrate modeling success.EPA、
6-gingerol exclusive use can be substantially reduced rat model whole blood contrast viscosity, plasma viscosity, illustrate that EPA, 6-gingerol can change
Kind hemorheology.5 data of consolidated statement, the present composition have what is become apparent compared with EPA, the 6-gingerol of exclusive use
Improve the effect of rat model hemorheology.
Claims (9)
1. a kind of natural drug composition of prevention and cure of cardiovascular disease, which is characterized in that it is based on fish oil and Ginger P.E
Active ingredient is wanted, adds pharmaceutically acceptable auxiliary material and/or pharmaceutical preparation that other active components are prepared.
2. composition according to claim 1, it is characterised in that the fish oil is from mackerel, tuna, salmon, sturgeon
The abyssal fishes such as fish, long tail anchovy, sardine, catfish, trout, the fish oil include at least docosahexaenoic acid（DHA）, 20
Carbon 5 alkene acid（EPA）, arachidonic acid（AA）, gamma-Linolenic acid（GLA）Wait the one or more in polyunsaturated fatty acids；Into
One step, polyunsaturated fatty acid total content >=8% in the fish oil.
3. composition according to claim 1, it is characterised in that the Ginger P.E includes at least 6-gingerol, 8- ginger
One or more in the ginger phenolic compounds such as phenol, 10-gingerol, 12- gingerols, wherein ginger phenolic compounds content >=25%；Into one
Step ground, the ginger phenolic compounds are preferably 6-gingerol.
4. composition according to claim 1, it is characterised in that it is made of the raw material of following weight proportion：
1-250 parts of fish oil, 1-250 parts of Ginger P.E；
Further, said composition is made of the raw material of following weight proportion：
20-200 parts of fish oil, 15-180 parts of Ginger P.E；
Further, said composition is made of the raw material of following weight proportion：
50-120 parts of fish oil, 30-150 parts of Ginger P.E.
5. composition according to claim 1, it is characterised in that the other active components are selected from, and there is similar pharmacology to make
Natural drug or chemical synthetic drug.
6. composition according to claim 5, which is characterized in that natural drug is included but not in the other active components
It is limited to leaf of negundo chastetree, negundo chastetree fruit, pigeonpea, sensitive plant, eleusine indica, Chinese violet, passionflower, leaves of Hawthorn, uncaria, gynostemma pentaphylla, ginkgo
Leaf, radix scutellariae, lotus leaf, rhodiola root, Radix Glycyrrhizae, trollflower, Ficus microcarpa, Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, subprostrate sophora, cattail pollen, safflower, kuh-seng etc. or it
Active component and extract.
7. composition according to claim 5, which is characterized in that chemical synthetic drug includes in the other active components
But it is general to be not limited to nitroglycerin, Isosorbide Nitrate, nifedipine, diltiazem hydrochloride, Propranolol, Propafenone, Kato
Profit, Irb, rice sieve ground that, Lovastatin, Bezafibrate, clofibrate, Ji Feibei top grades.
8. pharmaceutical composition according to claim 1, which is characterized in that the pharmaceutical preparation is with the drug system of oral administration
Based on agent, include but not limited to granule, tablet, capsule, pill, oral liquid, powder.
9. according to the application of pharmaceutical composition prepared by claim 1-8 in preventing or/and treating angiocardiopathy, the heart
Vascular diseases include but not limited to atherosclerosis, coronary heart diseases and angina pectoris, cerebral thrombus, hypertension, hyperglycaemia, hyperlipidemia, the heart
The diseases such as flesh infarct, ischemic pulmonary heart disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611007653.8A CN108066723A (en) | 2016-11-16 | 2016-11-16 | A kind of natural drug composition of prevention and cure of cardiovascular disease and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611007653.8A CN108066723A (en) | 2016-11-16 | 2016-11-16 | A kind of natural drug composition of prevention and cure of cardiovascular disease and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108066723A true CN108066723A (en) | 2018-05-25 |
Family
ID=62163265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611007653.8A Pending CN108066723A (en) | 2016-11-16 | 2016-11-16 | A kind of natural drug composition of prevention and cure of cardiovascular disease and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108066723A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109512803A (en) * | 2018-12-10 | 2019-03-26 | 广州医科大学附属第二医院 | A kind of agonist of Adenylate cyclase and its application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178281A (en) * | 2011-03-23 | 2011-09-14 | 荣成百合生物技术有限公司 | Antioxidative composition for fish oil |
| CN102727841A (en) * | 2011-04-15 | 2012-10-17 | 吕维学 | Gingerol extract product, its extraction method and its application |
| CN105232523A (en) * | 2015-10-08 | 2016-01-13 | 成都普瑞法科技开发有限公司 | Natural drug combination for preventing and treating cardiovascular diseases and application thereof |
| CN105232525A (en) * | 2015-10-08 | 2016-01-13 | 成都普瑞法科技开发有限公司 | Hypolipidemic drug combination and application thereof |
| CN105250261A (en) * | 2015-11-19 | 2016-01-20 | 成都普瑞法科技开发有限公司 | Theaflavin-containing pharmaceutical composition and application thereof in the aspect of lowering blood fat |
-
2016
- 2016-11-16 CN CN201611007653.8A patent/CN108066723A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102178281A (en) * | 2011-03-23 | 2011-09-14 | 荣成百合生物技术有限公司 | Antioxidative composition for fish oil |
| CN102727841A (en) * | 2011-04-15 | 2012-10-17 | 吕维学 | Gingerol extract product, its extraction method and its application |
| CN105232523A (en) * | 2015-10-08 | 2016-01-13 | 成都普瑞法科技开发有限公司 | Natural drug combination for preventing and treating cardiovascular diseases and application thereof |
| CN105232525A (en) * | 2015-10-08 | 2016-01-13 | 成都普瑞法科技开发有限公司 | Hypolipidemic drug combination and application thereof |
| CN105250261A (en) * | 2015-11-19 | 2016-01-20 | 成都普瑞法科技开发有限公司 | Theaflavin-containing pharmaceutical composition and application thereof in the aspect of lowering blood fat |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109512803A (en) * | 2018-12-10 | 2019-03-26 | 广州医科大学附属第二医院 | A kind of agonist of Adenylate cyclase and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alok et al. | Herbal antioxidant in clinical practice: A review | |
| CN105535048A (en) | Application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout | |
| Amle et al. | Bioactive Herbal Medicine Use for Eye Sight: A Meta Analysis | |
| Khosh et al. | Natural approach to hypertension | |
| CN105232523A (en) | Natural drug combination for preventing and treating cardiovascular diseases and application thereof | |
| US10967027B2 (en) | Extracts of Cyclanthera pedata and formulations and uses thereof | |
| CN105250261A (en) | Theaflavin-containing pharmaceutical composition and application thereof in the aspect of lowering blood fat | |
| US20170173059A1 (en) | Novel Combination of Naturally Occurring Compounds to Assist With Suspected Mycobacterial Infections Related to Autoimmune Conditions | |
| CN102631391A (en) | Application of gynura divaricata in preparing lipid-lowering medicine or health-care food | |
| CN103284151A (en) | Omega-3 unsaturated vegetable combined oil with effect of reducing blood fat | |
| CN108066723A (en) | A kind of natural drug composition of prevention and cure of cardiovascular disease and its application | |
| CN104523829B (en) | A kind of propolis Radix Salviae Miltiorrhizae health food | |
| CN106727480B (en) | Fex-3 is preparing the application in anti-obesity drug | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| CN107913277A (en) | The purposes of the anti-uric acid nephropathy of tanshinone | |
| CN107183716A (en) | A kind of liver protection is dispelled wine health-care food composition and preparation method thereof | |
| JP2019501912A (en) | Use of citrus extract and isoacteoside in muscle protection | |
| CN102743458A (en) | Formula of health drug with effects blood fat regulating and immunity increasing | |
| Mishra et al. | Role of nutraceuticals in metabolic syndrome | |
| CN102091146A (en) | Composite containing gingko extract or monomer | |
| CN105596889A (en) | Antitumor composition containing resveratrol and preparation method of antitumor composition | |
| CN113842461B (en) | GABA for relieving and treating alcoholism and drunk discomfort A Receptor conjugates, compositions and uses thereof | |
| Koyama | Bioactive foods and herbs in prevention and treatment of cardiovascular disease | |
| Kindernay et al. | Beneficial Effects of Polyphenol-Rich Food Oils in Cardiovascular Health and Disease | |
| CN102772466A (en) | Application of chrysanthemum extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180525 |
|
| WD01 | Invention patent application deemed withdrawn after publication |